{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-002318","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.957873+00:00","generated_at":"2026-06-07T02:21:37.761416+00:00","sec_items":["1.01","3.02","3.03","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Avenue Therapeutics raises $5.0M via warrant exercise; issues new warrants at $0.3006, subject to shareholder approval","bullets":["Gross proceeds ~$5.0M from immediate cash exercise of 16.5M existing warrants at reduced exercise price of $0.3006/share.","New unregistered Series A and Series B warrants each to purchase up to 16.5M shares at $0.3006; exercisable only after stockholder approval.","Stockholder approval required to increase authorized shares and comply with Nasdaq Rule 5635(d); no voting rights until exercise.","Maxim Group acted as agent; fees: 3.5% on Jan 2023 warrants and 7.0% on Nov 2023 warrants, plus up to $15,000 expense reimbursement.","Company intends to use net proceeds for general corporate purposes; closing expected on or about January 9, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-002318","json":"https://secwatch.observer/filing/0001104659-24-002318.json","markdown":"https://secwatch.observer/filing/0001104659-24-002318.md","text":"https://secwatch.observer/filing/0001104659-24-002318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/0001104659-24-002318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/tm242240d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:21:37.761416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f0e09fd26115bb6f356fef1598cbe8d450d61c8","claim":"AVENUE THERAPEUTICS, INC. entered into Inducement Letters with certain investors (the Holders) valued at aggregate gross proceeds of approximately $5.0 million (effective 2025-01-05).","evidence_excerpt":"On January 5, 2024, Avenue Therapeutics, Inc. (the “Company ”) entered into (i) an inducement offer letter agreement (the “ January 2023 Investor Inducement Letter ”) with a certain investor (the “ January 2023 Investor ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1644963/000110465924002318/0001104659-24-002318-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors (the Holders)"},{"label":"Value","value":"aggregate gross proceeds of approximately $5.0 million"},{"label":"Effective","value":"2025-01-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}